The Latest Cardiac and Vascular News
Houston, TX, May 27, 2020 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — AngioSoma, Inc. (OTC: SOAN) (“AngioSoma” or the “Company”) is pleased to announce that the Company is focusing on development and commercialization of our coating for metal stents. A stent is an expandable “scaffold-like” device, usually constructed of a metallic material, that is inserted into an artery […]
Houston, TX, May 20, 2020 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — AngioSoma Inc. (OTC: SOAN) (“AngioSoma” or the “Company”) is pleased to announce that the Company’s peripheral arterial disease (“PAD”) product, Atherectomy Catheter II, is a catheter-based platform capable of treating a broad range of plaque types, including calcified plaque and addresses many of the limitations associated with […]
Houston, Jan. 15, 2020 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — AngioSoma Inc. (OTC: SOAN) (“AngioSoma” or the “Company”) is pleased to announce that we have acquired the unconditional ownership of the following intellectual property and the exclusive right to develop, formulate and market: · Method and Composition for Reducing Dysfunction in Angioplasty Procedures · Kit for Preventing […]
HOUSTON, Nov. 13, 2018 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — AngioSoma (OTC: SOAN), a leading biotechnology research and development company, announces today the execution of a letter of intent to pursue a relationship with Biomedix®. Biomedix® manufactures a noninvasive device, PADnet, that diagnoses Peripheral Artery Disease (PAD) in patients. Biomedix has over 1,000 PADnet devices […]
HOUSTON, TX, June 18, 2018 (GLOBE NEWSWIRE) — AngioSoma, Inc. (SOAN) is excited to announce that we have identified a regulatory firm who can assist taking our patented flagship drug, Liprostin™, through the FDA approval process. The regulatory firm will begin with a presubmission meeting with the FDA biologic group to obtain a regulatory strategy […]
